A new type of orally active anti-diabetic Zn(II)-dithiocarbamate complex

Life Sciences

Volumn 80, Issue 8, 2007, Pages 759-766

  Yoshikawa, Yutaka ^a   Adachi, Yusuke ^a   Sakurai, Hiromu ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Adiponectin; Blood glucose lowering effect; Improvement of insulin resistance; Insulinomimetic activity; Zn(II) dithiocarbamate complex

Indexed keywords

ADIPONECTIN; BIS(DIETHYLDITHIOCARBAMATE)ZINC COMPLEX; BIS(DIMETHYLDITHIOCARBAMATE)ZINC COMPLEX; BIS(N ETHYL N PHENYLDITHIOCARBAMATE)ZINC COMPLEX; BIS(PYRROLIDINE N DITHIOCARBAMATE)ZINC COMPLEX; GLUCOSE; INSULIN; LEPTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ZINC COMPLEX;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERTENSION; IC 50; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL CHEMISTRY; PROTEIN BLOOD LEVEL; RAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOCYTES; ADIPONECTIN; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCOSE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; ORGANOMETALLIC COMPOUNDS; THIOCARBAMATES; TRIGLYCERIDES; ZINC SULFATE;

ANIMALIA; MUS;

EID: 33846211027     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.11.003     Document Type: Article

References (57)

1. Adachi Y., and Sakurai H. Comparative study of insulin-mimetic activity of vanadium and zinc complexes. Biomedical Research on Trace Elements 15 4 (2004) 351-354
2. Adachi Y., and Sakurai H. Insulin-mimetic vanadyl(IV) complexes as evaluated by both glucose-uptake and inhibition of free fatty acids (FFA)-release in isolated rat adipocytes. Chemical and Pharmaceutical Bulletin 52 4 (2004) 428-433
3. Adachi Y., Yoshida J., Kodera Y., Yoshikawa Y., Kojima Y., and Sakurai H. A new insulin-mimetic bis(allixinato)zinc(II) complex: structure-activity relationship of zinc(II) complexes. Journal of Biological Inorganic Chemistry 9 7 (2004) 885-893
4. Aizawa-Abe M., Ogawa Y., Masuzaki H., Ebihara K., Satoh N., Iwai H., Matsuoka N., Hayashi T., Hosoda K., Inoue G., Yoshimasa Y., and Nakao K. Pathophysiological role of leptin in obesity-related hypertension. Journal of Clinical Investigation 105 9 (2000) 1243-1252
5. Tos V., Maran A., Vigili de Kreutzenberg S., Marchetto S., Tadiotto F., Bettio M., Marescotti M.C., Tiengo A., and Del Prato S. Mechanisms of acute and chronic hypoglycemic action of gliclazide. Acta Diabetologica 37 4 (2000) 201-206
6. Defronzo R.A. Lilly Lecture: The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37 6 (1988) 667-687
7. Fasshauer M., and Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 46 12 (2003) 1594-1603
8. Ferrari P., and Weidmann P. Insulin, insulin sensitivity, and hypertension. Journal of Hypertension 8 6 (1990) 491-500
9. Friedman J.M., and Halaas J.L. Leptin and regulation of body weight in mammals. Nature 395 6704 (1998) 763-770
10. Fujimoto S., Fujii K., Yasui H., Matsushita R., Takada J., and Sakurai H. Long-term acting and orally active vanadyl-methylpicolinate complex with hypoglycemic activity in streptozotocin-induced diabetic rats. Journal of Clinical Biochemistry and Nutrition 23 2 (1997) 113-129
11. Gandara D.R., Harvey W.H., Monaghan G.G., Perez E.A., Stokes C., Bryson J.C., Finn A.L., and Hesketh P.J. The delayed-emesis syndrome from cisplatin: phase III evaluation of ondansetron versus placebo. Seminars in Oncology 19 4 Suppl 10 (1992) 67-71
12. Hider R.C., Ejim R., Taylor P.D., Gale R., Huehns, and Porter J.B. Facilitated uptake of zinc into human erythrocytes. Biochemical Pharmacology 39 6 (1990) 1005-1012
13. Holman R.R., Cull C.A., and Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 22 6 (1999) 960-964
14. Hotamisligil G.S., and Speigelman B.M. Tumor necrosis factor alpha: a key component of the obesity diabetes link. Diabetes 43 11 (1994) 1271-1278
15. Isley W.L. Hepatotoxicity of thiazolidinediones. Expert Opinion on Drug Safety 2 6 (2003) 581-586
16. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Reviews 26 3 (2005) 439-451
17. Kelly G.S. Insulin resistance: lifestyle and nutritional interventions. Alternative Medicine Review 5 2 (2000) 109-132
18. Kamon J., Yamauchi T., Muto S., Takekawa S., Ito Y., Hada Y., Ogawa W., Itai A., Kasuga M., Tobe K., and Kadowaki T. A novel IKKβ inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochemical and Biophysical Research Communications 323 1 (2004) 242-248
19. Kaplan N.M., and Opie L.H. Controversies in hypertension. Lancet 367 9505 (2006) 168-176
20. Koerner A., Kratzsch J., and Kiess W. Adipocytokines: leptin-the classical, resistin-the controversical, adiponectin-the promising, and more to come. Best Practice and Research in Clinical Endocrinology and Metabolism 19 4 (2005) 525-546
21. Koya D., and King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes 47 6 (1998) 859-866
22. Landsberg L. Hyperinsulinemia: possible role in obesity-induced hypertension. Hypertension 19 1 Suppl (1992) 161-166
23. Lechleitner M., Roden M., Haehling E., and Mueller M. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wiener Klinische Wochenschrift 117 17 (2005) 593-598
24. Manrique C., Lastra G., Whaley-Connell A., and Sowers J.R. Hypertension and the cardiometabolic syndrome. Journal of Clinical Hypertension 7 8 (2005) 471-476
25. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Letters 580 12 (2006) 2917-2921
26. Min Y.K., Park J.H., Chong S.A., Kim Y.S., Ahn Y.S., Seo J.T., Bae Y.S., and Chung K.C. Pyrrolidine dithiocarbamate-induced neuronal cell death is mediated by Akt, casein kinase 2, c-Jun N-terminal kinase, and IkappaB kinase in embryonic hippocampal progenitor cells. Journal of Neuroscience Research 71 5 (2003) 689-700
27. Moellering D., McAndrew J., Jo H., and Darley-Usmar V.M. Effect of pyrrolidine dithiocarbamate on endothelial cells: protection against oxidative stress. Free Radical Biology & Medicine 26 9-10 (1999) 1138-1145
28. Montani J.P., Antic V., Yang Z., and Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. International Journal of Obesity 26 Suppl. 2 (2002) S28-S38
29. Nakai M., Watanabe H., Fujisawa C., Kakegawa H., Satoh T., Takeda J., Matsushita R., and Sakurai H. Mechanism of insulin-like action of vanadyl sulfate: studies on interaction between rat adipocytes and vanadium compounds. Biological & Pharmaceutical Bulletin 18 5 (1995) 719-725
30. Nishimura M. Breeding of mice strains for diabetes mellitus. Experimental Animals 18 (1969) 147-157
31. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., Hotta K., Nishida M., Takahashi M., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100 25 (1999) 2473-2476
32. Pfutzner A., Schondorf T., Seidel D., Winkler K., Matthaei S., Hamann A., and Forst T. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism 55 1 (2006) 20-25
33. Rahmouni K., and Haynes W.G. Leptin signaling pathways in the central nervous system: interactions between neuropeptide Y and melanocortins. BioEssays 23 12 (2001) 1095-1099
34. Reaven G.M. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Medica 47 4 (2005) 201-210
35. Rocchini A.P. Obesity hypertension. American Journal of Hypertension 15 2 pt 2 (2002) 50S-52S
36. Sakurai H. A new concept: the use of vanadium complexes in the treatment of diabetes mellitus. Chemical Record 2 4 (2002) 237-248
37. Sakurai H., and Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals 18 4 (2005) 319-323
38. Sakurai H., Tsuchiya K., Nukatsuka M., Kawada J., Ishikawa S., Yoshida H., and Komatsu M. Insulin-mimetic action of vanadyl complexes. Journal of Clinical Biochemistry and Nutrition 8 3 (1990) 193-200
39. Sakurai H., Watanabe H., Tamura H., Yasui H., Matsushita R., and Takada J. Insulin-mimetic vanadyl-dithiocarbamate complexes. Inorganica Chimica Acta 283 1 (1998) 175-183
40. Sakurai H., Kojima Y., Yoshikawa Y., Kawabe K., and Yasui H. Antidiabetic vanadium(IV) and zinc(II) complexes. Coordination Chemistry Reviews 226 1-2 (2002) 187-198
41. Sakurai H., Yasui H., and Adachi Y. The therapeutic potential of insulin-mimetic vanadium. Expert Opinion on Investigational Drugs 12 7 (2003) 1189-1203
42. Sharma A.M., and Chetty V.T. Obesity, hypertension and insulin resistance. Acta Diabetologica 42 Suppl 1 (2005) S3-S8
43. Smith A.C. In: Martini L. (Ed). Encyclopedia of Endocrine Diseases vol. 3 (2004), Elsevier Science, San Diego 100-105
44. Tan X., and Shay N.F. Zinc has an insulin-like effect on glucose transport mediated by phosphoinositol-3-kinase and akt in 3T3-L1 fibroblasts and adipocytes. Journal of Nutrition 131 5 (2001) 1414-1420
45. The diabetes control and complications trial research group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New England Journal of Medicine 329 14 (1993) 977-986
46. Ueda E., Yoshikawa Y., Ishino Y., Sakurai H., and Kojima Y. Potential insulinomimetic agents of zinc(II) complexes with picolinamide derivatives: preparations of complexes, in vitro and in vivo studies. Chemical and Pharmaceutical Bulletin 50 3 (2002) 337-340
47. Watanabe H., Nakai M., Komazawa K., and Sakurai H. A new orally active insulin-mimetic vanadyl complex: bis(pyrrolidine-N-carbodithioato)oxovanadium (IV). Journal of Medicinal Chemistry 37 7 (1994) 876-877
48. Yoshida A., Yoshida S., Ishibashi T., Kuwano M., and Inomata H. Suppression of retinal neovascularization by the NF-kB inhibitor pyrrolidine dithiocarbamate in mice. Investigative Ophthalmology & Visual Science 40 7 (1999) 1624-1629
49. 4) coordination mode -in vitro and in vivo studies-. Biomedical Research on Trace Elements 16 4 (2005) 358-360
50. 2) coordination mode. Chemical and Pharmaceutical Bulletin 49 5 (2001) 652-654
51. y mice with type 2 diabetes mellitus. Biochemical and Biophysical Research Communications 281 5 (2001) 1190-1193
52. Yoshikawa Y., Kawabe K., Tadokoro M., Suzuki N., Yanagihara N., Nakayama A., and Kojima Y. New zinc(II) complexes with tetradentate amino acid derivatives: structure characterization, solution chemistry, and in vitro insulinomimetic activity. Bulletin of the Chemical Society of Japan 75 11 (2002) 2423-2432
53. 2) coordination mode: structure characterization, in vitro, and in vivo studies. Journal of Biological Inorganic Chemistry 7 1-2 (2002) 68-73
54. Yoshikawa Y., Ueda E., Sakurai H., and Kojima Y. Anti-diabetes effect of Zn(II)/Carnitine complex by oral administration. Chemical and Pharmaceutical Bulletin 51 8 (2003) 230-231
55. Yoshikawa Y., Ueda E., Kojima Y., and Sakurai H. The action mechanism of zinc(II) complexes with insulinomimetic activity in rat adipocytes. Life Sciences 75 6 (2004) 741-751
56. Yoshikawa Y., Kondo M., Sakurai H., and Kojima Y. A family of insulinomimetic zinc(II) complexes of amino ligands with Zn(Nn) (n = 3 or 4) coordination modes. Journal of Inorganic Biochemistry 99 7 (2005) 1497-1503
57. Zimmet P., Alberti K.G.M.M., and Shaw J. Global and societal implications of the diabetic apidemic. Nature 414 6865 (2001) 782-787